# Ian E. Krop

Source: https://onco.cc/people/ian-krop/  
OnCo record `ian-krop` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breast oncologist who took T-DM1 and then trastuzumab deruxtecan from first-in-human studies to approval.

## Summary

Ian Krop (Yale Cancer Center) led the early development of trastuzumab emtansine including its phase 1 and TH3RESA trials, and was a lead investigator of the DESTINY-Breast programme that made trastuzumab deruxtecan standard second-line therapy for HER2-positive disease. He chairs the Translational Breast Cancer Research Consortium and leads early-phase ADC trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; adc; her2
- Role: Associate Cancer Center Director for Clinical Research, Yale Cancer Center
- Specialisms: HER2-positive breast cancer; Antibody-drug conjugates; Early drug development

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Krop%20IE%5BAuthor%5D%20trastuzumab%20emtansine%20OR%20deruxtecan

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- institutions: [Yale Cancer Center / Smilow Cancer Hospital](https://onco.cc/institutions/yale-cancer-center/)
- trials: [DESTINY-Breast03](https://onco.cc/trials/destiny-breast03/)
- key papers: [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/ian-krop.json